Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 15, 2020

View Archived Issues

Enrollment ongoing in first-in-human study of JNJ-74856665 in AML or MDS

Phase II study of KN-046 in patients with thymic carcinoma begins

Aravive opens enrollment in phase Ib/II study of AVB-S6-500 in clear cell renal cell carcinoma

Missense variants in c-Myc, CDK4 and ARHGDIA genes identified as potential causes of MODY by WES

CureVac initiates pivotal phase IIb/III study of CVnCoV

TCR2 presents positive interim data from ongoing phase I/II study of gavo-cel

ADU-S100 plus pembrolizumab appears well tolerated in recurrent/metastatic HNSCC

AB-729 results in robust reduction in HBsAg in patients with chronic hepatitis B

Nuclear receptors protect against kidney disease

First patient dosed in phase II BLUEPRINT study of BLU-5937

Arvinas reports interim clinical data for ARV-471 and ARV-110

FDA clears IND for phase I study of LB-1901 in relapsed or refractory T-cell lymphoma

Voronoi patents FLT3 and/or MAP4K1 and/or CDK6/cyclin D1 inhibitors

U.S. researchers synthesize new KRAS mutant inhibitors

Gilead Sciences identifies MAP4K1 inhibitors

Poxel presents further phase IIa data for PXL-770 in NASH

Bolting TLR agonist to antibody converts cold tumors

InvisiMask human antibody nasal spray protects against SARS-CoV-2 infection in vivo

BioTheryX presents new GSPT1 inhibitors

Phase III KESTREL study of Beovu in DME meets primary endpoint

Suzhou Ribo Life Science describes new PCSK9-targeting siRNA

Phase II trial examines DS-1062 for advanced or metastatic NSCLC with actionable genomic alterations

European Commission approves Trixeo Aerosphere for maintenance treatment of COPD

Mesoblast reports topline phase III data on Revascor in advanced chronic heart failure

SOD1G93A Grm5+/- mouse model highlights mGlu5 receptors as a target in amyotrophic lateral sclerosis

FDA approves Klisyri for actinic keratosis on the face or scalp

TOT Biopharm presents promising phase I data for trastuzumab ADC TAA-013

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 17, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 17, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
European Commission floats multiple fixes for MDR, IVDR
BioWorld MedTech
The European Union’s struggles with regulations for devices and in vitro diagnostics seem virtually endless, but the European Commission floated a series of...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.